Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Endo Pharmaceuticals Inc. v. Actavis, Inc.
Case Number:
13-1658
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
June 04, 2014
Fed. Circ. Lets Endo Opana Patent Win Stand
The Federal Circuit on Tuesday declined bids by Roxane Laboratories Inc. and Actavis Inc. to review a panel's ruling that settlements allowing the companies to sell generic versions of Endo Pharmaceuticals Inc.'s painkiller Opana ER did not include licenses for later Opana patents.
-
May 01, 2014
Actavis Seeks En Banc Review Of Fed. Circ. Endo IP Ruling
Actavis Inc. urged the Federal Circuit on Wednesday to rehear en banc the company's appeal of a ruling that settlements allowing the sale of generic versions of Endo Pharmaceuticals Inc.'s painkiller Opana ER didn't include licenses for later Opana patents, saying the opinion disregarded "a century of precedent."
-
March 31, 2014
Fed. Circ. Says Generics Deals Exclude Endo's New Patents
The Federal Circuit ruled Monday that settlements allowing Roxane Laboratories Inc. and Actavis Inc. to sell generic versions of Endo Pharmaceuticals Inc.'s painkiller Opana ER did not include licenses for later Opana patents, reversing a lower court's denial of an injunction on sales of the generics.